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Abstract By binding to the benzodiazepine site, diaze-
pam binding inhibitor (DBI) is associated with negative
allosteric modulation (NAM) of GABAA receptors (Costa
and Guidotti in Life Sci 49:325–344, 1991). However, the
demonstration of a true physiological role of DBI and its
fragments has only recently been reported. Based on DBI
gain- and loss-of-function experiments in vivo, DBI and its
fragment ODN were found to promote neurogenesis in the
subventricular zone in vivo. Acting as NAM on GABAA
receptors of precursor cells, DBI counteracted the inhibi-
tory effect of GABA and thereby enhanced the prolifera-
tion of these cells (Alfonso et al. in Cell Stem Cell
10:76–87, 2012). Conversely and most remarkably, in
similar gain- and loss-of-function experiments in the thal-
amus, the DBI gene products acted as positive allosteric
modulators (PAM) of GABAA receptors in prolonging the
duration of IPSCs, an effect which was specific for GABA
transmission within the reticular nucleus (nRT) (Christian
et al. in Neuron 78:1063–1074, 2013). Since intra-nRT
potentiation of GABA transmission by benzodiazepine
drugs exerts powerful anti-oscillatory effects, DBI might
be endogenously effective by modulating seizure suscep-
tibility. It remains to be seen by which mechanism both
NAM and PAM activity can arise from the Dbi gene.
Nevertheless, the results open new perspectives on the
regionally distinct endogenous modulation of GABA
transmission via the benzodiazepine site.
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The Quest for Endogenous Ligands
Benzodiazepines have remained one of the most commonly
prescribed medications in the field of psychiatry and neu-
rology. Thanks to their potency, efficacy, short onset of
action and low toxicity, benzodiazepines are widely used as
anti-anxiety, anticonvulsant, sedative and muscle-relaxing
drugs. All these effects are due to increasing the amplitude
or duration of inhibitory postsynaptic currents mediated by
GABAA receptors, thereby enhancing inhibitory synaptic
transmission by interacting with a specific benzodiazepine
drug target site of the receptors, originally termed benzo-
diazepine receptor [4].
The discovery of the benzodiazepine receptor [5, 6] led
to the hypothesis that the brain produces endogenous
ligands that bind to this site and serve as endogenous allo-
steric modulators of GABAA receptors with the potential of
contributing to human disease. Endogenous ligands were
perceived to potentially act as positive allosteric modulators
(PAM, also termed agonists) or negative allosteric modu-
lators (NAM, also termed inverse agonists) [1, 7]. Several
naturally occurring candidate compounds were isolated
from brain tissue such as diazepam binding inhibitor (DBI)
[1, 7, 8], oleamides [9] and non-peptidic endozepines [10],
of which DBI was most widely studied. DBI fragments were
recently proposed to serve as regionally selective, physio-
logical regulators acting at the benzodiazepine site of
GABAA receptors, as summarized below.
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DBI and Its Multiple Pharmacological Actions
DBI, also known as acyl-CoA binding protein [11], is a
small cytosolic protein (10 kDa) expressed predominantly
in glia and ependymal cells lining the ventricles [2, 12] that
is secreted into the extracellular space via a non-conven-
tional secretary pathway [13]. DBI and its proteolytic
peptide products octadecaneuropeptide (ODN) and tria-
kontatetraneuropeptide (TTN) bind to the central benzodi-
azepine site of GABAA receptors and/or the socalled
peripheral benzodiazepine receptor site [1] a 18 kDa
mitochondrial translocator protein (TSPO) involved in the
regulation of steroid synthesis [14]. DBI and ODN inter-
acted with high affinity with the central benzodiazepine
receptor site of GABA-A receptors (Ki = 4 micromolar in
3H-diazepam binding), while the TTN fragment of DBI had
a preferential affinity for the peripheral benzodiazepine site
(Ki = 5 micromolar in 3H Ro5-4864 binding) [1, 7, 8, 15].
When injected icv into rats, DBI, ODN and TTN all showed
anxiogenic activity [16]. However, in keeping with the
target distinction, the effect of DBI and ODN was antago-
nized by flumazenil while that of TTN was antagonized by
PK11195, the peripheral site antagonist, but not by flu-
mazenil [16]. Correspondingly, TTN and similarly DBI, but
not ODN, enhanced steroidogenesis [17]. Thus, DBI gives
rise to functionally distinct biologically active fragments.
However, their functional role in vivo was only recently
discovered.
Negative Allosteric Modulation of GABAA Receptors
by ODN in Neurogenesis In Vivo
The subventricular zone (SVZ) of the lateral ventricles is
the largest neurogenic niche of the postnatal brain. New
SVZ-generated neurons migrate via the rostral lateral
stream to the olfactory bulb where they integrate in pre-
existing circuits. Non-synaptic GABA signaling is known
to inhibit SVZ-derived neurogenesis [18, 19] with GABA
being released from neuroblasts [2].
The GABAA receptor modulator DBI is highly expressed
in the SVZ. To test its potential regulatory role in neuro-
genesis, DBI loss- and gain-of- function experiments were
performed in vivo at the peak of postnatal neuron generation
in mice (P4–P8) [2]. DBI knockdown in vivo by retroviral
injection of shRNA impaired proliferation in the SVZ niche
as shown by a decrease of cells stained positive for BrdU, a
marker of dividing cells, as determined 12 days post injec-
tion. The specificity of the DBI knockdown effect was ver-
ified by a rescue of the impaired proliferation through
retroviral expression of DBI in shRNA-DBI-infected cells. A
gain-of-function experiment in vivo further substantiated the
role of DBI in neuronal proliferation. Injection of a DBI
overexpressing virus into the SVZ of mice (P4) increased
proliferation of neuronal SVZ progenitor cells. Thus, DBI
loss- and gain-of-function experiments had opposite effects,
in line with DBI being a positive regulator of subventricular
neurogenesis.
The enhanced postnatal neuronal proliferation induced
by DBI was mediated via the central benzodiazepine site of
GABAA receptors, not the peripheral/mitochondrial ben-
zodiazepine site [2]. In primary cultures containing neur-
ospheres of SVZ progenitor cells, DBI expression induced
proliferation, in agreement with the in vivo results. The
DBI effect was blocked by flumazenil but not PK11195,
suggesting that DBI acted via GABAA receptors.
Remarkably, ODN replicated the DBI effects in vivo
and similarly induced neuronal proliferation following
retroviral overexpression of ODN in the SVZ [2]. This
effect was based on ODN acting as NAM of GABAA
receptors as shown in patch clamp experiments in fast
proliferating progenitor cells. Thus, in the regulation of
neurogenesis, DBI is expressed and released from neural
stem cells and fast proliferating progenitor cells and pro-
cessed to ODN which attenuates GABAA receptor medi-
ated inward currents on neural progenitors. ODN thereby
counteracts the GABAergic brake on subventricular neu-
ronal proliferation [2]. Thus, for the first time evidence for
a physiological function of DBI and ODN as NAM of
GABAA receptors has been provided in a defined cellular
context in vivo.
Positive Allosteric Modulation of GABAA Receptors
by DBI in Suppressing Thalamic Activity In Vivo
In contrast to DBI acting as NAM as described above, a
physiological role of DBI acting as endogenous PAM of
GABAA receptors was recently identified [3]. The thalamo-
cortical (TC) circuit is normally involved in sleep rhythms
and sensory processing [20] and abnormal oscillatory
activity in this circuit can promote absence seizures [21].
The thalamic reticular nucleus (nRT) is posed to play a
critical role in gating this circuit. The nRT receives excit-
atory input from both cortico-thalamic and thalamocortical
axons (Fig. 1). The nRT provides GABAergic inhibitory
input onto TC relay cells in dorsal thalamus such as the
ventrobasal nucleus (VB) and enforces intranuclear inhi-
bition via recurrent collaterals [21] (Fig. 1).
A reduction in intra-nRT inhibition results in hypersyn-
chronous epileptiform oscillations between nRT and VB
[22]. Conversely, a gain of intra-nRT inhibition dampens
oscillatory duration. Modulation of intra-nRT inhibition can
thus shape TC circuit activity and thereby influences seizure
susceptibility and duration. Benzodiazepines can suppress
these thalamocortical oscillations by enhancing inhibition
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within nRT via a3GABAA receptors [22]. Individuals with a
mutation of the c2 subunit of the GABAA receptor, which
disrupts the benzodiazepine receptor site commonly develop
absence seizures [23]. It was therefore hypothesized that an
endogenous PAM resides within the nRT to enhance syn-
aptic inhibition and thereby limiting TC oscillations.
Evidence of a PAM residing in the nRT, which poten-
tiates GABAergic transmission was based on loss-and
gain-of function experiments [3]. In slices from mice with
a point mutated a3 subunit [a3(H126R)] which renders the
benzodiazepine site diazepam-insensitive, whole cell
recordings in nRT revealed a reduced duration of GABA-
induced and spontaneous IPSCs compared to wild type
(Fig. 1). The response to GABA itself was unaltered by the
point-mutation as shown by the responses of outside-out
patches to laser-evoked GABA uncaging, suggesting that
the GABA-dependent receptor operation was comparable
in wt and mutant animals and did not account for the dif-
ferences observed in IPSCs. In addition, flumazenil
reduced the IPSC duration in slices of wt but not mutant
mice. These findings were in line with the presence of an
endogenous PAM in the nRT [3]. Remarkably, when
examining the adjacent VB thalamic nucleus, flumazenil
failed to affect the duration of the IPSCs. To exclude the
possibility that differences in the composition of GABAA
receptors in nRT and VB would account for the different
responses, sniffer patch experiments were performed in
thalamic slices combined with GABA uncaging. A patch
pulled from the VB neurons exposed to the nRT, displayed
an increased duration of the GABA response compared to
VB suggesting that differences in receptor composition did
not account for the distinctive response to flumazenil
between nRT and VB [3].
Evidence on the molecular nature of the PAM in nRT
came from mice lacking a 400 kb region of chromosome 1
(mm1054) which comprises the Dbi gene. Like the a3
(H126R) mice, the mm1054 mice showed a reduced
duration of the IPSC in the nRT [3]. Importantly, this IPSC
deficit was rescued by viral expression of DBI, demon-
strating that the loss of this gene was sufficient to account
for the reduced IPSC duration [3]. These findings provide
strong evidence that the Dbi gene encodes the endogenous
PAM which acts within the nRT as physiological modu-
lator of GABAA receptors. In addition, this is first evidence
of a physiologically relevant PAM to arise from the Dbi
gene. Furthermore, the results led to the suggestion that
PAM release within the TC circuit may reduce seizure
susceptibility and severity through a slowing of the seizure
oscillations, which may destabilize them.
An Endogenous PAM Regulating Vigilance
in Hypersomnia?
In a recent study [24], in which flumazenil normalized vig-
ilance in patients with non-hypocretin-deficient primary
hypersomnias, the presence of a peptidergic PAM was found
in CSF. A CSF fraction of 500–3,000 Da enhanced, in a
trypsin-sensitive manner, GABA-induced chloride currents,
acting preferentially at a2 subunit- compared to a1 subunit-
containing recombinant GABAA receptors (176.4 ± 41.3
vs. 71.4 ± 36.4 %). However, this potentiation did not
affect a potentiation by midazolam and partly persisted in
a1(H101R) GABAA receptors, indicating that it may not be a
classical benzodiazepine-mimicking agent [24]. The chem-
ical nature of this CSF constituent and its potential role in the
pathophysiology of hypersomnia remains to be resolved.
An improvement in vigilance by administration of flu-
mazenil had been reported earlier in some patients with
hepatic encephalopathy [25, 26], sleep deprivation [27, 28]
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Fig. 1 Duration of GABA-induced IPSC shortened in the thalamic
reticular nucleus (nRT) of a3(H126R) GABAA receptor mutant mice.
Left: Averaged eIPSC traces across thalamic reticular nucleus cells
recorded from WT mice (lower trace) and a3 (H126R) mutant mice
(upper trace) and the corresponding bar graph. Black dot indicates
time of electrical stimulation applied to nRT [3]. Right: Scheme of
the TC circuit. Excitatory thalamic relay neurons largely express a1
GABAA receptors. GABA neurons (light gray) within the reticular
nucleus express a3 GABAA receptors [21] respectively
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and idiopathic recurrent stupor [29]. These findings
remained inconclusive with regard to an endogenous PAM
since flumazenil itself, depending on the paradigm in
question, can display partial inverse agonistic activity or
partial agonistic activity [31]. Nevertheless, in the case of
recurrent stupor, a small molecular weight, non-peptidergic
bioactivity, termed endozepine-4, was increased in CSF
during ictal periods up to 300-fold [30]. Although
endozepine-4, like other endozepines of this type, were
purified from rat and human brain and potentiated GABA
evoked chloride currents [10], their chemical nature was
not resolved and was partly attributed to environmental/
nutritional sources [32].
Future Directions
The search for the elusive endogenous ligand for the ben-
zodiazepine site of GABAA receptors has closed in on a
longstanding suspect, DBI and its proteolytic fragments [2,
3]. Most remarkably, the endogenous ligands exploit the
ability of GABAA receptors to undergo positive (in the case
of nRT) as well as negative (in the case of neurogenesis)
allosteric modulation, which up to now seemed to be a
prerogative for pharmacological ligands. Several questions
remain [33]. In thalamus, PAM effects were only detect-
able within the nRT although the Dbi gene is likewise
expressed in the VB. How are regionally and functionally
distinct peptides derived from the Dbi gene? Are there cell-
specific peptide products being generated? Could post-
translational modifications result in opposing effects? Is
DBI or a DBI fragment operative as endogenous ligand in
other parts of the CNS and PNS? Answers to these ques-
tions would substantiate the claims for DBI and may open a
new chapter in the regional regulation of GABA trans-
mission. The findings may also shed new light on a
potential regional efficacy modulation by drugs acting at
the benzodiazepine site.
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